{"id":20145,"date":"2025-03-19T14:03:47","date_gmt":"2025-03-19T14:03:47","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/jacobio-pharma-announces-2024-annual-results\/"},"modified":"2025-03-19T14:03:47","modified_gmt":"2025-03-19T14:03:47","slug":"jacobio-pharma-announces-2024-annual-results","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=20145","title":{"rendered":"Jacobio Pharma Announces 2024 Annual Results"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BEIJING<\/span>, <span class=\"xn-location\">SHANGHAI<\/span> and <span class=\"xn-location\">BOSTON<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 19, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160\u00a0million, R&amp;D expense of <span class=\"xn-money\">RMB330 million<\/span>. Major operating and financing activities generated <span class=\"xn-money\">RMB320 million<\/span> cash inflows. By the end of 2024, cash and bank balances and bank credit balances amounted to <span class=\"xn-money\">RMB1.45 billion<\/span>. Jacobio also announced recent business progress and expected milestones.<\/p>\n<p>&#8220;2024 is a transforatmive year for Jacobio. We have submitted a New Drug Application (NDA) for the KRAS G12C inhibitor glecirasib and have licensed out the <span class=\"xn-location\">China<\/span> rights of glecirasib and the <span class=\"xn-money\">SHP2<\/span> inhibitor sitneprotafib to our partner. This marks\u00a0 Jacobio&#8217;s\u00a0 successful transformation\u00a0 from the early R&amp;D stage to an innovation-driven value realization stage,&#8221; said Dr.Yinxiang Wang, the Chairman and CEO of Jacobio Pharma. &#8220;Looking ahead to 2025, glecirasib is expected to receive the official approval for marking, which will continuously generate cash flow to invest in Jacobio&#8217; subsequent pipeline.&#8221;<\/p>\n<p>Development of core clinical stage products<\/p>\n<p>Glecirasib (JAB-21822, KRAS G12C inhibitor) and sitneprotafib (JAB-3312, <span class=\"xn-money\">SHP2<\/span> inhibitor)<\/p>\n<ul type=\"disc\">\n<li>The commercialization and further clinical development in <span class=\"xn-location\">China<\/span> of glecirasib and sitneprotafib were licensed to Allist on <span class=\"xn-chron\">August 30, 2024<\/span>.<\/li>\n<li>Non-small cell lung cancer (NSCLC)\n<ul type=\"disc\">\n<li>The\u00a0NDA application of glecirasib monotherapy in second-line and above NSCLC was submitted to the CDE (China Drug Evaluation Center) in <span class=\"xn-chron\">May 2024<\/span> and the priority review designation was granted in the same month. Glecirasib is expected to be approved in the first half of 2025.<\/li>\n<li>The Phase III pivotal trial of\u00a0glecirasib combined with sitneprotafib in front-line NSCLC enrolled the first patient in <span class=\"xn-location\">China<\/span> on <span class=\"xn-chron\">August 7, 2024<\/span>.<\/li>\n<\/ul>\n<\/li>\n<li>Multi-tumor basket\n<ul type=\"disc\">\n<li>The multi-tumor basket registration phase II trial of\u00a0glecirasib for the treatment of pancreatic cancer, biliary tract cancer, gastric cancer, small bowel cancer, appendiceal cancer and other indications has been initiated in <span class=\"xn-location\">China<\/span>. Glecirasib has received orphan drug designation (ODD) from FDA and EMA for pancreatic cancer.<\/li>\n<\/ul>\n<\/li>\n<li>Colorectal cancer\n<ul type=\"disc\">\n<li>The Phase III trial of\u00a0glecirasib mono or in combination with cetuximab in third line was approved by the CDE in <span class=\"xn-chron\">May 2024<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>JAB-23E73 (pan-KRAS inhibitor)<\/p>\n<ul type=\"disc\">\n<li>The IND (Investigational New Drug) applications were approved in <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">the United States<\/span> in <span class=\"xn-chron\">September 2024<\/span><\/li>\n<li>The first patient was enrolled in <span class=\"xn-chron\">November 2024<\/span><\/li>\n<li>The dose escalation phase is expected to be completed in the second half of 2025<\/li>\n<\/ul>\n<p>JAB-30355 (p53 Y220C activator)<\/p>\n<ul type=\"disc\">\n<li>The IND application of FIH (first-in-human) global trial of JAB-30355 was approved by the FDA in <span class=\"xn-chron\">March 2024<\/span> and by the CDE in <span class=\"xn-chron\">June 2024<\/span>.<\/li>\n<li>The first patient was enrolled in <span class=\"xn-chron\">July 2024<\/span><\/li>\n<li>The dose escalation is expected to be completed in the second half of 2025<\/li>\n<\/ul>\n<p>JAB-8263 (BET inhibitor)<\/p>\n<ul type=\"disc\">\n<li>The dose escalation for JAB-8263 in solid tumors and hematologic malignancy were completed in the U.S. and <span class=\"xn-location\">China<\/span>, respectively. The RP2D (phase II recommended doses) was obtained.<\/li>\n<li>Dose expansion in patients with myelofibrosis is ongoing.<\/li>\n<li>Solid tumor portion with specific biomarkers is being explored. .<\/li>\n<\/ul>\n<p>JAB-2485 (Aurora A inhibitor)<\/p>\n<ul type=\"disc\">\n<li>A Phase I\/IIa global trial of JAB-2485 is ongoing in the U.S. and <span class=\"xn-location\">China<\/span>.<\/li>\n<li>Dose escalation phase is expected to be completed in the first half of 2025<\/li>\n<li>The expansion of monotherapy and combination with chemotherapy are being planned.<\/li>\n<\/ul>\n<p><b>Development of pre-clinical pipelines <\/b><\/p>\n<p>JAB-BX467 (HER2-STING iADC)<\/p>\n<ul type=\"disc\">\n<li>Clinical candidate of HER2-STING iADC has been nominated in the second half of 2024.<\/li>\n<li>The IND application is being planned to be submitted in 2026.<\/li>\n<\/ul>\n<p>JAB-BX600 (KRAS G12D ADC)<\/p>\n<ul type=\"disc\">\n<li>The clinical candidate is expected to be nominated in the second half of 2025.<\/li>\n<\/ul>\n<p>As of <span class=\"xn-chron\">December 31, 2024<\/span>, Jacobio has filed more than 360 patent applications worldwide, including 126 authorized patents.<\/p>\n<p><b>Conference call information<\/b><\/p>\n<p>Jacobio Pharma will hold a conference call at <span class=\"xn-chron\">9:30 AM<\/span> (<span class=\"xn-location\">Beijing<\/span> time) on <span class=\"xn-chron\">March 20, 2024<\/span>. Participants, please register in advance through this link: <a href=\"https:\/\/s.comein.cn\/hdqi2zrx\" target=\"_blank\" rel=\"nofollow\">https:\/\/s.comein.cn\/hdqi2zrx<\/a><\/p>\n<p><b>About Jacobio Pharma<\/b><\/p>\n<p>Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform,\u00a0the company&#8217;s\u00a0core projects\u00a0focus\u00a0on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation.\u00a0Jacobio&#8217;s\u00a0\u00a0R&amp;D centers are located in <span class=\"xn-location\">Beijing<\/span>, <span class=\"xn-location\">Shanghai<\/span> (<span class=\"xn-location\">China<\/span>), and <span class=\"xn-location\">Boston<\/span> (<span class=\"xn-location\">USA<\/span>). Clinical trials are conducted\u00a0at over 180 sites in <span class=\"xn-location\">China<\/span>, more than 30 sites in the <span class=\"xn-location\">USA<\/span>, and over 10 sites\u00a0across\u00a0several European countries. For more information, please visit:\u00a0<a href=\"http:\/\/www.jacobiopharma.com\/\" target=\"_blank\" rel=\"nofollow\">http:\/\/www.jacobiopharma.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BEIJING<\/span>, <span class=\"xn-location\">SHANGHAI<\/span> and <span class=\"xn-location\">BOSTON<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 19, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160\u00a0million, R&amp;D expense of <span class=\"xn-money\">RMB330 million<\/span>. Major operating and financing activities generated <span class=\"xn-money\">RMB320 million<\/span> cash inflows. By the end of 2024, cash and bank balances and bank credit balances amounted to <span class=\"xn-money\">RMB1.45 billion<\/span>. Jacobio also announced recent business progress and expected milestones.<\/p>\n<p>&#8220;2024 is a transforatmive year for Jacobio. We have submitted a New Drug Application (NDA) for the KRAS G12C inhibitor glecirasib and have licensed out the <span class=\"xn-location\">China<\/span> rights of glecirasib and the <span class=\"xn-money\">SHP2<\/span> inhibitor sitneprotafib to our partner. This marks\u00a0 Jacobio&#8217;s\u00a0 successful transformation\u00a0 from the early R&amp;D stage to an innovation-driven value realization stage,&#8221; said Dr.Yinxiang Wang, the Chairman and CEO of Jacobio Pharma. &#8220;Looking ahead to 2025, glecirasib is expected to receive the official approval for marking, which will continuously generate cash flow to invest in Jacobio&#8217; subsequent pipeline.&#8221;<\/p>\n<p>Development of core clinical stage products<\/p>\n<p>Glecirasib (JAB-21822, KRAS G12C inhibitor) and sitneprotafib (JAB-3312, <span class=\"xn-money\">SHP2<\/span> inhibitor)<\/p>\n<ul type=\"disc\">\n<li>The commercialization and further clinical development in <span class=\"xn-location\">China<\/span> of glecirasib and sitneprotafib were licensed to Allist on <span class=\"xn-chron\">August 30, 2024<\/span>.<\/li>\n<li>Non-small cell lung cancer (NSCLC)\n<ul type=\"disc\">\n<li>The\u00a0NDA application of glecirasib monotherapy in second-line and above NSCLC was submitted to the CDE (China Drug Evaluation Center) in <span class=\"xn-chron\">May 2024<\/span> and the priority review designation was granted in the same month. Glecirasib is expected to be approved in the first half of 2025.<\/li>\n<li>The Phase III pivotal trial of\u00a0glecirasib combined with sitneprotafib in front-line NSCLC enrolled the first patient in <span class=\"xn-location\">China<\/span> on <span class=\"xn-chron\">August 7, 2024<\/span>.<\/li>\n<\/ul>\n<\/li>\n<li>Multi-tumor basket\n<ul type=\"disc\">\n<li>The multi-tumor basket registration phase II trial of\u00a0glecirasib for the treatment of pancreatic cancer, biliary tract cancer, gastric cancer, small bowel cancer, appendiceal cancer and other indications has been initiated in <span class=\"xn-location\">China<\/span>. Glecirasib has received orphan drug designation (ODD) from FDA and EMA for pancreatic cancer.<\/li>\n<\/ul>\n<\/li>\n<li>Colorectal cancer\n<ul type=\"disc\">\n<li>The Phase III trial of\u00a0glecirasib mono or in combination with cetuximab in third line was approved by the CDE in <span class=\"xn-chron\">May 2024<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>JAB-23E73 (pan-KRAS inhibitor)<\/p>\n<ul type=\"disc\">\n<li>The IND (Investigational New Drug) applications were approved in <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">the United States<\/span> in <span class=\"xn-chron\">September 2024<\/span><\/li>\n<li>The first patient was enrolled in <span class=\"xn-chron\">November 2024<\/span><\/li>\n<li>The dose escalation phase is expected to be completed in the second half of 2025<\/li>\n<\/ul>\n<p>JAB-30355 (p53 Y220C activator)<\/p>\n<ul type=\"disc\">\n<li>The IND application of FIH (first-in-human) global trial of JAB-30355 was approved by the FDA in <span class=\"xn-chron\">March 2024<\/span> and by the CDE in <span class=\"xn-chron\">June 2024<\/span>.<\/li>\n<li>The first patient was enrolled in <span class=\"xn-chron\">July 2024<\/span><\/li>\n<li>The dose escalation is expected to be completed in the second half of 2025<\/li>\n<\/ul>\n<p>JAB-8263 (BET inhibitor)<\/p>\n<ul type=\"disc\">\n<li>The dose escalation for JAB-8263 in solid tumors and hematologic malignancy were completed in the U.S. and <span class=\"xn-location\">China<\/span>, respectively. The RP2D (phase II recommended doses) was obtained.<\/li>\n<li>Dose expansion in patients with myelofibrosis is ongoing.<\/li>\n<li>Solid tumor portion with specific biomarkers is being explored. .<\/li>\n<\/ul>\n<p>JAB-2485 (Aurora A inhibitor)<\/p>\n<ul type=\"disc\">\n<li>A Phase I\/IIa global trial of JAB-2485 is ongoing in the U.S. and <span class=\"xn-location\">China<\/span>.<\/li>\n<li>Dose escalation phase is expected to be completed in the first half of 2025<\/li>\n<li>The expansion of monotherapy and combination with chemotherapy are being planned.<\/li>\n<\/ul>\n<p><b>Development of pre-clinical pipelines <\/b><\/p>\n<p>JAB-BX467 (HER2-STING iADC)<\/p>\n<ul type=\"disc\">\n<li>Clinical candidate of HER2-STING iADC has been nominated in the second half of 2024.<\/li>\n<li>The IND application is being planned to be submitted in 2026.<\/li>\n<\/ul>\n<p>JAB-BX600 (KRAS G12D ADC)<\/p>\n<ul type=\"disc\">\n<li>The clinical candidate is expected to be nominated in the second half of 2025.<\/li>\n<\/ul>\n<p>As of <span class=\"xn-chron\">December 31, 2024<\/span>, Jacobio has filed more than 360 patent applications worldwide, including 126 authorized patents.<\/p>\n<p><b>Conference call information<\/b><\/p>\n<p>Jacobio Pharma will hold a conference call at <span class=\"xn-chron\">9:30 AM<\/span> (<span class=\"xn-location\">Beijing<\/span> time) on <span class=\"xn-chron\">March 20, 2024<\/span>. Participants, please register in advance through this link: <a href=\"https:\/\/s.comein.cn\/hdqi2zrx\" target=\"_blank\" rel=\"nofollow\">https:\/\/s.comein.cn\/hdqi2zrx<\/a><\/p>\n<p><b>About Jacobio Pharma<\/b><\/p>\n<p>Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform,\u00a0the company&#8217;s\u00a0core projects\u00a0focus\u00a0on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation.\u00a0Jacobio&#8217;s\u00a0\u00a0R&amp;D centers are located in <span class=\"xn-location\">Beijing<\/span>, <span class=\"xn-location\">Shanghai<\/span> (<span class=\"xn-location\">China<\/span>), and <span class=\"xn-location\">Boston<\/span> (<span class=\"xn-location\">USA<\/span>). Clinical trials are conducted\u00a0at over 180 sites in <span class=\"xn-location\">China<\/span>, more than 30 sites in the <span class=\"xn-location\">USA<\/span>, and over 10 sites\u00a0across\u00a0several European countries. For more information, please visit:\u00a0<a href=\"http:\/\/www.jacobiopharma.com\/\" target=\"_blank\" rel=\"nofollow\">http:\/\/www.jacobiopharma.com<\/a><\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-20145","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/20145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20145"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/20145\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}